BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.

Q4 2024 Earnings Call Transcript February 19, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.64, expectations were $0.54. Operator: Ladies and gentlemen, thank you ...

A single gene in the shorebird species known as ruffs controls the levels of testosterone in males, and this in turn affects ...

A team of Chinese scientists has used targeted gene editing to develop rice that produces coenzyme Q10 (CoQ10), a vital ...

A virus originally found in animals, mpox -- which causes the disease of the same name -- is now circulating in humans. Since 2022, it has been the cause of major epidemics spreading outside endemic ...

We view Avita’s RECELL system as a sound alternative treatment for large second- and third-degree burns treated in burn centers. It compares favorably on price and ease of use with new products and ...

DSM-Firmenich is selling its 50% stake in the Feed Enzymes Alliance to its partner Novonesis for 1.5 billion euros ($1.55 billion). The Dutch nutrition, health and bioscience company said Tuesday that ...

It is a unique member of the plastic family as it can be broken down into its constituent units (or monomers) by PETases, which are enzymes that degrade PET. Until now, scientists have discovered ...

Four U.S. Army units, including the 2nd Mobile Brigade Combat Team, 101st Airborne Division and a Chemical, Biological, Radiological, and Nuclear Battalion will deploy overseas this spring.

Engineered enzymes are poised to have transformative impacts across applications in energy, materials, biotechnology, and medicine. Recently, machine learning has emerged as a useful tool for ...